SEGMENTED INFORMATION

6 Months Ended

Jun. 30, 2024

SEGMENTED INFORMATION

SEGMENTED INFORMATION

NOTE 11 – SEGMENTED INFORMATION

At June 30, 2024, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia (formerly known as Bionexus Gene Lab Sdn. Bhd.) and Chemrex.

	BioNexus Gene Lab Corp.
	a Wyoming company
100% owned		100% owned
MRNA Scientific Sdn. Bhd. (formerly “Bionexus Gene Lab Sdn. Bhd.”),		Chemrex Corporation Sdn. Bhd.,
a Malaysian company		a Malaysian Company

At June 30, 2024, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex.

For the six months ended June 30, 2024, segmented (unaudited) revenue and net (loss)/profit (Currency expressed in United States Dollars (“US$”) are as follows:

	MRNA Scientific			Chemrex Corporation			BGLC			Total
	Six months ended June 2024
REVENUE	$	8,661		$	4,347,754		$	-		$	4,356,415
COST OF REVENUE		(4,605	)		(3,698,059	)		-			(3,702,664	)
GROSS PROFIT		4,056			649,695			-			653,751
OTHER INCOME		76,058			855,894			-			931,952
OPERATING EXPENSES
General and administrative		(185,218	)		(696,763	)		(523,582	)		(1,405,563	)
(LOSS)/PROFIT FROM OPERATIONS		(105,104	)		808,826			(523,582	)		180,140
FINANCE COSTS		(4,595	)		(4,433	)		(113	)		(9,141	)
(LOSS)/PROFIT BEFORE TAX		(109,699	)		804,393			(523,695	)		170,999
Tax expense		-			(75,652	)		-			(75,652	)
NET (LOSS)/PROFIT	$	(109,699	)	$	728,741		$	(523,695	)	$	95,347

	MRNA Scientific			Chemrex Corporation			BGLC			Total
				Six months ended June 30, 2023
REVENUE	$	11,932		$	4,932,121		$	-		$	4,944,053
COST OF REVENUE		(7,548	)		(4,227,894	)		-			(4,235,442	)
GROSS PROFIT		4,384			704,227			-			708,611
OTHER INCOME		2,165			310,343			-			312,508
OPERATING EXPENSES
General and administrative		(98,720	)		(1,025,896	)		(219,333	)		(1,343,949	)
LOSS FROM OPERATIONS		(92,171	)		(11,326	)		(219,333	)		(322,830	)
FINANCE COSTS		(1,275	)		(4,212	)		-			(5,487	)
LOSS BEFORE TAX		(93,446	)		(15,538	)		(219,333	)		(328,317	)
Tax expense		-			-			-			-
NET LOSS	$	(93,446	)	$	(15,538	)	$	(219,333	)	$	(328,317	)

	As of June 30, 2024 and December 31, 2023
	Total Assets				Total Liabilities
	2024		2023		2024		2023
BGLC & MRNA Scientific	$	4,380,021		4,723,449	$	616,300	$	260,119
Chemrex Corporation		6,759,706		6,676,344		977,673		1,481,822
TOTAL		11,139,727		11,399,793		1,593,973		1,741,941